Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Staging PET/CT Better Defines Extent of Mantle Cell Lymphoma

Publish date:: September 19, 2019

Key clinical point: 18F-fluorodeoxyglucose PET/CT helps stage mantle cell lymphoma, sometimes altering management.

Major finding: Compared with CT alone, PET/CT led to upstaging in 17% of patients and down-staging in 2% of patients.

Study details: A two-center retrospective cohort study of 122 patients with mantle cell lymphoma.

Disclosures: No outside funding was disclosed. Dr. Albano reported having no relevant conflicts of interest.

Citation:

Albano D et al. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e457-64.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,